Search Results
Sep 09, 2026, 09:05 ET BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
by which bone tissue is created, is negatively regulated due to a gain of function mutation in FGFR3. VOXZOGO, a C-type natriuretic peptide (CNP) analog, acts as a positive regulator of the signaling pathway downstream of FGFR3 to promote endochondral bone growth. VOXZOGO is the
More news about: BioMarin Pharmaceutical Inc.
Sep 09, 2026, 09:04 ET Onix Expands Its Trusted AI Platform With $5 Million USD Pre-Seed Round
Nathalie Niddam, CNP, BPC, longevity and biohacking expert;
More news about: Onix
Aug 31, 2026, 06:58 ET CenterPoint Energy Activates Emergency Operations Center as it continues Taking Action to Prepare Ahead of Potential Impacts from Invest 97L Across Southeast Texas including Greater Houston
CenterPointEnergy.com/ActionCenter. About CenterPoint Energy, Inc. As the only investor owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more
More news about: CenterPoint Energy
Aug 31, 2026, 02:00 ET BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
of California.Reaching this agreement recognizes the value of BioMarin's pioneering innovations in C-type natriuretic peptide (CNP) technology, including the development of VOXZOGO® (vosoritide), while providing a framework that enables continued access to medicine for
More news about: BioMarin Pharmaceutical Inc.
Aug 13, 2026, 11:09 ET New Economic Study: Southeast Texas Transmission Resiliency Projects Could Deliver Over $18 Billion in Positive Economic Impact for Local Texas Communities
others.About CenterPoint Energy, Inc. As the only investor owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more
More news about: CenterPoint Energy
Aug 11, 2026, 07:01 ET CenterPoint Energy Announces Historic "Customer Savings Initiative" Projecting $5 Billion in Affordability Savings for Texas Electric Customers Over the Next Decade
commitment.About CenterPoint Energy, Inc. As the only investor owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more
More news about: CenterPoint Energy, Inc
Aug 06, 2026, 16:03 ET BioMarin Reports Second Quarter 2026 Financial and Operating Results
natriuretic peptide (CNP) for achondroplasia. In a single-ascending-dose study in healthy adults, BMN 333 demonstrated sustained exposure supporting weekly dosing and was well tolerated, with free CNP exposure at the highest dose more than 13-fold that of another long-acting CNP agent, reflecting its
More news about: BioMarin Pharmaceutical Inc.
Jul 29, 2026, 04:39 ET Global Pump Market Size to Exceed USD 88.36 Billion by 2031 as Smart Pump Adoption Expands Across Industries - Arizton
Ltd.WeatherfordOther Prominent Company ProfilesAtlas Copco ABArian PumpsAR North AmericaCNP India Private LimitedCP Pumpen AGDickow Pump CompanyGlobal PumpGorman-Rupp PumpHaight PumpsHERMETIC-PUMPENHCP
More news about: Arizton Advisory & Intelligence
Jul 16, 2026, 09:34 ET CenterPoint Energy Declares Regular Common Stock Dividend of $0.2400
HOUSTON, July 16, 2026 /PRNewswire/ -- CenterPoint Energy, Inc.'s (NYSE: CNP) Board of Directors yesterday declared a regular quarterly cash dividend of $0.2400 per share on the issued and outstanding shares of Common Stock payable
More news about: CenterPoint Energy, Inc
Jul 13, 2026, 09:05 ET U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia
by which bone tissue is created, is negatively regulated due to a gain of function mutation in FGFR3. VOXZOGO, a C-type natriuretic peptide (CNP) analog, acts as a positive regulator of the signaling pathway downstream of FGFR3 to promote endochondral bone growth.VOXZOGO is the only
More news about: BioMarin Pharmaceutical Inc.
Jun 16, 2026, 09:05 ET BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
engagement, supporting a weekly dosing schedule. The maximum examined dose of BMN 333 (500 μg/kg) increased exposure to free CNP by more than 13 times compared to another long-acting CNP agent, reflecting the potential of BMN 333 to become the new standard of care in achondroplasia. BMN 333 was well tolerated
More news about: BioMarin Pharmaceutical Inc.
Jun 09, 2026, 03:30 ET Café de la Bourse dévoile les lauréats des Trophées de l'Investissement 2026
YomoniLucya CNPMeilleur PER
More news about: CAFEDELABOURSE.COM
Jun 01, 2026, 09:07 ET CenterPoint Energy Advances Extreme Weather Preparedness and Response Efforts with Integrated, AI‑Driven Planning Platform from Technosylva
time.About CenterPoint Energy, Inc.As the only investor owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more
More news about: Technosylva
May 14, 2026, 18:02 ET CenterPoint Energy conducts full-scale emergency exercise in preparation for 2026 hurricane season
www.CenterPointEnergy.com/TakingAction.About CenterPoint Energy, Inc. As the only investor owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more
More news about: CenterPoint Energy
May 04, 2026, 16:05 ET BioMarin Reports First Quarter 2026 Financial and Operating Results
year-end.In April, the first patient was enrolled in the registration-enabling Phase 2/3 study of BMN 333, BioMarin's long-acting C-type natriuretic peptide (CNP) for achondroplasia. A data update from this study is expected in 2027.In April, the company submitted its U.S. supplemental new drug application
More news about: BioMarin Pharmaceutical Inc.
May 02, 2026, 15:30 ET BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting
by which bone tissue is created, is negatively regulated due to a gain of function mutation in FGFR3. VOXZOGO, a C-type natriuretic peptide (CNP) analog, acts as a positive regulator of the signaling pathway downstream of FGFR3 to promote endochondral bone growth.VOXZOGO is the only
More news about: BioMarin Pharmaceutical Inc.
Apr 30, 2026, 08:15 ET Annals of Family Medicine: Mayo Clinic study details treatment options family medicine physicians may consider to treat ME/CFS and long COVID
Specialist EvaluationStephanie L. Grach, MD, MS; Jaime Seltzer, MS; Michael R. Mueller, MD; Chris A. Aakre, MD; Lasonya T. Natividad, APRN, CNP, MSN; Donna K. Lawson, CCRP; Ravindra Ganesh, MBBS, MD; and Ryan T. Hurt, MD, PhD
More news about: Annals of Family Medicine
Apr 22, 2026, 08:30 ET Esquire Bank Ranked Among Top 25 U.S. Merchant Acquirers by Nilson Report
increase.Ranked 14th nationally in card-not-present (CNP) purchase volume, which grew 9.4% to $14.01 billion.Settled more than 590 million total purchase transactions, including 209.6 million CNP transactions."Our merchant services vertical is a core
More news about: Esquire Financial Holdings, Inc.
Apr 16, 2026, 18:15 ET CenterPoint Energy appoints Michael A. "Casey" Herman to Board of Directors
April 16, 2026 /PRNewswire/ -- As part of the ongoing refreshment process of its Board of Directors, CenterPoint Energy (NYSE: CNP) today announced that its shareholders elected a new Director, Michael A. ("Casey") Herman to its Board, effective April 16, 2026. Herman brings decades
More news about: CenterPoint Energy
Apr 16, 2026, 18:10 ET CenterPoint Energy Declares Regular Common Stock Dividend of $0.2300
HOUSTON, April 16, 2026 /PRNewswire/ -- CenterPoint Energy, Inc.'s (NYSE: CNP) Board of Directors today declared a regular quarterly cash dividend of $0.2300 per share on the issued and outstanding shares of Common Stock payable
More news about: CenterPoint Energy
Apr 10, 2026, 11:00 ET Ohio Recognized with AANA's Excellence in State Government Relations Advocacy Award
day. Ohio legislators also learned about nurse anesthesiology "from within," after OSANA supported the successful campaign of Kellie Deeter, DNP, CRNA, CNP, to become the first CRNA elected to the Ohio House of Representatives.Among OSANA's recent legislative achievements, Ohio officially passed nondiscrimination
More news about: American Association of Nurse Anesthesiology
Mar 26, 2026, 16:38 ET BioMarin apresenta novos dados sobre o impacto positivo do tratamento precoce com VOXZOGO® (vosoritida) na proporcionalidade e envergadura dos braços em crianças com acondroplasia na Reunião Anual de Genética Clínica de 2026 do Colégio Americano de Genética Médica e Genômica (ACMG)
crescimento ósseo endocondral é reduzido devido a uma mutação de ganho de função no FGFR3. VOXZOGO (vosoritida), um análogo do peptídeo natriurético tipo C (CNP), atua regulando positivamente a via de sinalização downstream do FGFR3, promovendo o crescimento ósseo endocondral.Vosoritida é indicado
More news about: BioMarin
Mar 19, 2026, 03:33 ET Industrial Water & Wastewater Pump Market Worldwide to Reach USD 5.71 Billion by 2032, Driven by Expanding Wastewater Treatment Infrastructure | Vyansa Intelligence
PumpsGrundfosFlowserveSulzerKSBXylemPentairKirloskar Brothers LtdShanghai KaiquanCNPLEO GroupLianCheng GroupSHIMGEGlobal Industrial Water & Wastewater Pump Market ScopeBy
More news about: Vyansa Intelligence
Mar 12, 2026, 09:05 ET BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
by which bone tissue is created, is negatively regulated due to a gain of function mutation in FGFR3. VOXZOGO, a C-type natriuretic peptide (CNP) analog, acts as a positive regulator of the signaling pathway downstream of FGFR3 to promote endochondral bone growth.VOXZOGO is the only
More news about: BioMarin Pharmaceutical Inc.
Mar 07, 2026, 16:51 ET CGTN: China inicia do décimo quinto Plano Quinquenal com força total e abre oportunidades globais
considerado crucial para o desenvolvimento do país ao longo da segunda metade da década.Na manhã de quinta-feira, o 14º Congresso Nacional do Povo (CNP) — o principal órgão legislativo da China — abriu sua quarta sessão no Grande Salão do Povo, em Pequim. A reunião ocorreu um dia após o início da sessão
More news about: CGTN